Journals / Türk Anestezi ve Reanimasyon Dergisi / 2012 / Cilt: 40 - Sayı: 6

Neuroleptic malignant syndrome: a case report

Nöroleptik malign sendrom: olgu sunumu

Pages
329–331
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

By presenting this case, we aim to discuss the approaches to NMS and treatment modalities of NMS in light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic Malignant Syndrome (NMS) is usually seen in patients who use antipsychotic drugs and has a high mortality rate.
📊
Key Findings & Data:The 46-year-old male patient who had a history of 10 years of klozapin use due to schizophrenia applied to the emergency ser- vice with unconscionsness, speech disorder and high fever.
💡
Conclusion & Impact:By presenting this case, we aim to discuss the approaches to NMS and treatment modalities of NMS in light of the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic Malignant Syndrome (NMS) is usually seen in patients who use antipsychotic drugs and has a high mortality rate. It is a life-threatening con- dition associated with dopaminergic blockage. Symptoms include high fever, diaphoresis, unstable blood pressure, unconsciousness, muscular rigidity, and autonomic dysfunction. The 46-year-old male patient who had a history of 10 years of klozapin use due to schizophrenia applied to the emergency ser- vice with unconscionsness, speech disorder and high fever. Having a history of irregular use of medicine in the recent past, the patient was restarted with klozapin as his symptoms increased. During the neurological examination, he had impaired consciousness and muscular rigidity. The laboratory analysis revealed the leukocyte 13.800/mm3, AST: 2.067 U/L, ALT: 295 U/L, LDH: 5.709 U/L, CK-MB: 1.189 U/L, CK: 123.889 U/L. He was diagnosed as NMS. By presenting this case, we aim to discuss the approaches to NMS and treatment modalities of NMS in light of the literature.

Özet

Nöroleptik Malign Sendrom (NMS), genelde antipsikotik kullananlardagörülen bir sendromdur ve yüksek mortaliteye sahiptir. Hayati tehlikeoluşturan bir bozukluk olup, dopamin blokajı yapan antipsikotik ilaç kullanımı ile birliktedir. Semptomlar yüksek ateş, terleme, düzensiz kanbasıncı, bilinç bozukluğu, kaslarda rijidite ve otonomik disfonksiyonuiçerir. Şizofreni nedeniyle 10 yıldır klozapin kullanım öyküsü olan kırkaltı yaşındaki erkek hasta, bilinç ve konuşma bozukluğu, ateş yakınması ile acil servise başvurdu. Son dönemlerde düzensiz ilaç kullanım hikaye- si mevcut olan hastaya, semptomlarının artması üzerine tekrar klozapin başlandı. Nörolojik muayenede bilinç bozukluğu ve kas rijiditesi vardı.Laboratuvar incelemelerinde lökosit 13,800/mm3, AST: 2,067 U/L, ALT: 295 U/L, LDH: 5,709 U/L, CK-MB: 1,189 U/L, CK: 123,889 U/L idi. Hasta NMS olarak kabul edildi. Bu olgu sunumu ile NMS’ye yaklaşımı ve tedaviyi literatür eşliğinde tartışmayı amaçladık.

🔖

Cite This Article

KOÇOĞLU, H., YILDIZ, İ., DURAN, A., AKKAYA, A., TEKELİOĞLU, Ü. Y., DEMİRHAN, A., BAYIR, H. (2022). Neuroleptic malignant syndrome: a case report. Türk Anestezi ve Reanimasyon Dergisi, Cilt: 40 - Sayı: 6, 329–331. https://ajindex.com/articles/619816

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium- induced neuroleptic malignant syndrome. Ann Pharmacother 2006; 40: 139-42. [CrossRef] 2. Rasmussen KG. Risk factors for neuroleptic malignant syndrome. Am J Psychiatry 1998; 155: 1639-40. 3. Semiz ÜB. Nöroleptik Malign Sendrom. İçinde: Ceylan ME, Çetin M.(edit.). Şizofreni. 4. Baskı. İstanbul: İncekara Matbaacılık, 2009; 1167-76. 4. Kasantikul D, Kanchanatawan B. Neuroleptic malignant syndrome: a review and report of six cases. J Med Assoc Thai 2006; 89: 2155-60. 5. Hayashi H, Kawakatsu S, Watanabe K, Fukasawa T, Otani K. Neuro- leptic malignant syndrome complicated by massive intestinal bleeding in a patient with chronic renal failure. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1225-7. [CrossRef] 6. Keck PE, Pope HG, McElroy SL. Frequency and presentation of ne- uroleptic malignant syndrome: A prospective study. Am J Psychiatr 1992; 144: 1344. 7. Angelopoulos P, Markopoulou M, Kyamidis K, Bobotas K. Neurolep- tic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride. Gen Hosp Psychiatry 2008; 30: 482-4. [CrossRef] 8. Ording H, Ranklev E, Fletcher R. Investigation of malignant hypert- hermia in Denmark and Sweden. Br J Anaesth 1984; 56: 1183-90. [CrossRef] 9. Miyaoka H, Shishikura K, Otsubo T, Muramatsu D, Kamijima K. Di- azepamresponsive neuroleptic malignant syndrome: a diagnostic subt- ype? Am J Psychiatry 1997; 154: 882. 10. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malig- nant syndrome. Are dantrolene and bromocriptine useful adjuncts to suppor- tive care? Br J Psychiatry 1991; 159: 709-12. [CrossRef]